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blood coagulation status are disclosed. The method includes
positioning a sample probe containing an optical fiber within
a circulating blood; transmitting a low-coherence light
through the optical fiber into the blood; detecting dynamic
light scatter signals generated by the blood within a coherence volume and received through the optical fiber; analyzing
the dynamic light scatter signals in comparison to a predetermined coagulation criterion; and reporting the coagulation
status of the blood. The method can be used for monitoring
blood coagulation status in vivo or in vitro in real time.
Further disclosed is a method of determining blood clotting
time in vitro using the optical coagulation monitor.
25 Claims, 9 Drawing Sheets
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OPTICAL COAGULATION MONITOR AND
METHOD OF USE

and control the therapeutic treatment. Moreover, it is also
desirable to effectively monitor coagulation activities in vitro,
and provide improved detection method for determining clotting time.

FIELD OF THE INVENTION
The present invention relates to optical coagulation monitors based on low-coherence dynamic light scattering measurement for determining or monitoring blood coagulation
status in vivo or in vitro in real time and for measurement of
blood clotting time in vitro.

SUMMARY OF THE INVENTION

10

BACKGROUND OF THE INVENTION
Blood clotting is a complex process involving multiple
initiators and cascades of activators which ultimately lead to
the formation of fibrin and eventually to insoluble fibrin clots.
The blood clotting process is an indicator of serious pathological conditions including thrombosis, pulmonary embolism, heart attack, stroke, and coronary artery disease which is
the primary cause of mortality in the United States.
Conventionally, blood clotting process is assessed by measuring the time taken for a sample of blood to clot naturally or
after a specific chemical coagulation initiator is introduced.
The most commonly used tests for measuring the blood clotting time are the activated partial thromboplastin time (aPTT)
test and prothrombin time (PT) test. The former is initiated by
kaolin, PL (an emulsion of negatively charged phospholipids ), and calcium; and the latter is initiated by thromboplastin
and calcium. The conventional methods for determining the
time of clot formations are typically based on mechanical,
acoustical or electrical technologies. These methods are relatively slow and the instruments involved can be relatively
bulky.
Optical measurements have been used in determining
blood clotting time in vitro. U.S. Pat. No. 4,777,141 (to Calzi
et al) discloses an instrument for measuring coagulation
parameters, in which plasma and a reagent is mixed and a
light scatter measurement is made on the mixture. The light
scatter measurement is based on the transition of an initial
homogenous liquid phase to a heterogeneous light-solid
phase in which the threads of insoluble fibrin are formed.
U.S. Pat. No. 5,039,617 (McDonald et al) discloses a capillary flow device and the method for measuring activated
partial thromoplastin time. This method performs an APTT
analysis on a whole blood sample to which no anticoagulant
has been added, by applying the sample to a capillary track,
and by detecting the cessation of blood flow as determined by
a light scatter measurement on blood cells passing through a
specific location of the track.
On the other hand, U.S. Pat. No. 6,958,816 (to Dogariu et
al) discloses methods and systems that use dynamic light
scattering, for investigating local rheological responses of
complex fluids over a frequency range larger than that provided by standard instrumentation.
Currently, no instrument is available for monitoring blood
coagulation status in vivo in real time. It is known that patients
who have undergone major surgery are at great risk of thrombosis up to 72 hrs after surgery. Under these conditions any
significant increase in blood viscosity may most probably
indicate the onset of thrombosis.
Therefore, there is a strong need for instrumentations and
methodologies that enable early detection of clotting activation in real time, so that early therapeutic intervention can be
started timely to avert thrombosis and death. Furthermore,
there is further a strong need in the ability of monitoring the
effectiveness of procoagulant or anticoagulant therapies in
real time, which would allow the physicians to understand
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In one aspect, the present invention is directed to an optical
coagulation monitor, which comprises a sample chamber
including an inlet and an outlet connected to a circulation
path; a light source providing a low-coherence light; a sample
probe disposed within the sample chamber, the sample probe
comprising an optical fiber optically connected to the light
source for transmitting the low-coherence light into a blood
sample contained in the sample chamber; an optical detector
connected to the sample probe for detecting light signals
received from the sample probe; and a dynamic light signal
analyzer connected to the optical detector. The optical fiber
can be a single-mode optical fiber or a multi-mode optical
fiber.
In a further aspect, the present invention is directed to a
method of determining or monitoring blood coagulation status. In one embodiment, the method comprises positioning a
sample probe comprising an optical fiber within a circulating
blood; transmitting a low-coherence light through the optical
fiber into the blood; detecting dynamic light scatter signals
generated by the blood within a coherence volume and
received through the optical fiber; analyzing the dynamic
light scatter signals in comparison to a predetermined coagulation criterion; and reporting a coagulation status of the
blood. The monitoring blood coagulation status is in real
time, and the circulating blood can be either in vivo or in vitro.
In one embodiment, analyzing the dynamic light scatter
signals of the blood cells generates a power spectrum of
intensity vs. frequency. The predetermined coagulation criterion can be a predetermined value or a range of one or more
parameters obtained from the power spectrum; a shape or a
rate of change in the shape of the power spectrum; a predetermined amount of change of storage modulus G', loss
modulus G", or loss tangent tano. In another embodiment,
analyzing the dynamic light scatter signals of the blood cells
generates temporal autocorrelation of the dynamic light scatter signals. The predetermined coagulation criterion can be a
predetermined value or a range of one or more parameters
obtained from the temporal autocorrelation, or a predetermined amount of change in the shape of the temporal autocorrelation, or in the width of the temporal autocorrelation.
In a further aspect, the present invention is directed to a
method of determining blood clotting time in vitro. In one
embodiment, the method comprises mixing a coagulation
initiator with a blood sample to form a sample mixture; transmitting a low-coherence light into the sample mixture; detecting dynamic light scatter signals generated by the sample
mixture within a coherence volume; analyzing the light signals in comparison to a predetermined clotting criterion; and
reporting the blood clotting time of the blood sample. The
sample mixture is in a flowing or static condition during the
detection.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic illustration of the optical coagulation
monitor of one embodiment of the present invention.
FIG. 2 illustrates a portion of a multi-mode optical coagulation monitor in one embodiment of the present invention.
FIG. 3 shows the power spectra of a whole blood sample
obtained using the optical coagulation monitors with a single-
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mode optical fiber and a multi-mode optical fiber, as
described in Examples 1 and 2, respectively.
FIG. 4 shows the power spectra of the reconstructed whole
blood samples with different levels of hematocrit, as
described in Example 3.
FIG. 5 shows the power spectra of a blood sample obtained
at different time after addition of thrombin, as described in
Example 4.
FIG. 6 shows the power spectra of a blood sample obtained
at different time after addition of thrombin, as described in
Example 5.
FIG. 7 is a log-log representation of FIG. 6, showing the
changes in the slope of the power spectra, as described in
Example 5.
FIG. 8 shows the power spectra of washed red blood cells
suspended in PBS and in PBS solutions containing different
concentrations offibrinogen, as described in Example 6.
FIG. 9 shows the power spectra of washed red blood cells
suspended in PBS and after addition of albumin in the PBS, as
described in Example 6.

used to control the circulating blood at about 37° C. Other
suitable temperature control device can also be used for the
purpose of the present invention, for example, a semiconductor peltier.
Sample probe 20 comprises an optical fiber 80 which is
also referred to as the sample branch of the optical detection
system. Optical fiber 80 connects to fiber optic splitter 100 at
its one end 84 and the opposing end 82, which is referred to as
the sampling end hereinafter, is disposed within sample
chamber210 and immersed within the whole blood sample to
be measured. Optical fiber 80 can be either a single-mode or
a multi-mode optical fiber, as described in more detail below.
In one exemplary embodiment, sample probe 20 includes a
needle 22 with optical fiber 80 embedded within the needle,
and with sampling end 82 of optical fiber 80 disposed at the
end of needle 22 and exposing to the blood.
The light source 50 provides a low-coherence light. Preferably, the low-coherence light has a coherence length from
about 5 µm to about 50 µm, and more preferably, from 8 µm
to about 20 µm. Suitable low-coherence light source includes,
but is not limited to, superluminescent diode (SLD), a multiple quantum well light emitting diode (MQWLED), a modelocked Ti:Al 2 0 3 laser, a laser pumped fluorescent organic
dye, and a superfluorescent optical fiber.
In an exemplary embodiment as illustrated in Example 1, a
superluminescent diode (SLD) is used as the light source. In
FIG. 1, the component 40 is a SLD current and temperature
controller for the SLD light source.
The low-coherence light generated by light source 50 is
transmitted by optical isolator 60 to sample probe 20. In one
embodiment, optical isolator 60 is a fiber based. A fiber optic
splitter lOOa or a fiber optic coupler lOOb connects to optical
isolator 60 and optical detector 70 at one side and to optical
fiber 80 of sample probe 20 at the other side. The fiber optic
splitter or coupler directs the low-coherence light from light
source 50 into optical fiber 80 of sample probe 20, and at the
same time directs the light signals received from the sampling
end 82 of optical fiber 80 to optical detector 70.
Optical detector 70 detects the light signals received from
optical fiber 80 of sample probe 20. The light signals are
converted by detector 70 to electrical signals, which are fed
into a two-channel dynamic light signal analyzer 110. The
two-channel dynamic light signal analyzer 110 can typically
operate in the Fast Fourier Transform (FFT) mode with a base
Frequency of 100 Hz and 800 FFT lines. The data generated
by dynamic light signal analyzer 110 can be input to, through
a general protocol interface board (GPIB) controller, and
further processed by a personal computer 120.
In one embodiment, the optical coagulation monitor utilizes a single-mode optical fiber, which is also referred to as a
single-mode optical coagulation monitor. Herein, the term
"single-mode" optical fiber refers to an optical fiber having a
narrow core diameter that only permits transmission of substantially one mode light signal. The term "multi-mode" optical fiber refers to an optical fiber having a broader core diameter that permits transmission of multiple modes of light
signals. It is noted that the term "optical fiber" used herein
includes gradient index and step index fibers, and specialty
fibers such as photonic crystal fiber and structured fibers, etc.
In the single-mode optical coagulation monitor, both optical isolator 60 and optical fiber 80 of sample probe 20 are a
single-mode optical fiber, and a fiber optic splitter lOOa is
used. For the low-coherence light used for the purpose of the
present invention, the single-mode optical fiber can have a
fiber core diameter from about 6 µm to about 8 µm. In one
exemplary embodiment, a single-mode optical fiber having a
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DETAILED DESCRIPTION OF THE INVENTION
In one aspect, the present invention provides optical coagulation monitors for monitoring blood coagulation status in
vivo or in vitro, or for measurement of blood clotting time in
vitro.
In one embodiment, the optical coagulation monitor comprises a sample chamber connected to a circulation path, a
low-coherence light source, a sample probe comprising optical fiber, an optical detector, and a dynamic light signal analyzer. FIG. 1 illustrates a schematic diagram of the optical
coagulation monitor in one embodiment of the present invention. Herein, the term of dynamic light signal analyzer refers
to a light signal analyzer that enables analysis of dynamic
light signals. The term of dynamic light signals refers to
time-dependent fluctuations observed when light is scattered
by moving scattering centers such that the distance between
them is constantly changing in time. Because of the constructive and destructive interferences in the scattered light, its
intensity fluctuates in time and carries information about the
movement of the scattering centers. This fluctuating intensity
can be analyzed in either time or frequency domain.
More specifically, the optical coagulation monitor shown
in FIG. 1 includes two major segments. The first segment
includes the low-coherence light source and dynamic light
scatter detection components, and the second segment
includes a blood circulation system for conditioning blood
sample for coagulation measurement in vitro.
Referring to FIG. 1, the blood circulation system 200
includes a sample chamber 210, which has an inlet 212 and an
outlet 214, connected to a circulation path 220. In one exemplary embodiment, circulation path 220 is formed by a silicone tubing with its two opposing ends connected to inlet 212
and outlet 214. A pump 230 is connected to circulation path
220 for circulating the blood within circulation path 220.
Typically, the blood to be measured is circulated at a low flow
rate, for example, from about 0.05 to about 1.5 ml per minute.
The interior surface of the circulation path is compatible to
whole blood samples, which does not induce, or is resistant
to, protein precipitation. Sample chamber 210 can further
include a reagent inlet (not shown) for introducing a coagulation initiator.
Preferably, the temperature of the blood within the circulation path is controlled at about physiological temperature
by a temperature control device (not shown). In one exemplary embodiment shown in Example 1, a water bath 250 is
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wavelength of 630 run, a fiber inner jacket of 125 µm, and a
fiber core thickness of 8 µm is used. The terminators can be
FC/PC.
In a further embodiment, the optical coagulation monitor
utilizes a multi-mode optical fiber, which is referred to as a
multi-mode optical coagulation monitor. Because the reference optical path is generated by reflection at the end of the
fiber used to generate the measuring signal also, this interferometer is also referred to as multi-mode common path interferometer. In the multi-mode optical coagulation monitor,
two figurations can be used. In one configuration, both optical
isolator and optical fiber of sample probe are a multi-mode
optical fiber, and a fiber optic coupler llOb is used
In an alternative configuration as illustrated in FIG. 2, in
the multi-mode optical coagulation monitor 300 a singlemode optical fiber 60a is connected to light source 50 at one
end, and the other end is coupled to a multi-mode optical fiber
360 by a coupler 330. Multi-mode optical fiber 360 is in tum
connected to fiber optic coupler lOOb. For the low-coherence
light used for the purpose of the present invention, the multimode optical fiber can have a fiber core diameter from about
40 µm to about 50 µm. In one exemplary embodiment, multimode optical fiber 60b and 380 have a wavelength of 630 run,
a fiber inner jacket of 125 µm thick, and a fiber core thickness
of50 µm. The single-mode optical fiber 60a coupled to multimode optical fiber 360 has a wavelength of 630 run, a fiber
inner jacket of 125 µm thick, and a fiber core thickness of 8
µm.
As can be further appreciated from the schematic illustration of FIG. 2, for monitoring coagulation status in vivo,
sample probe 320 can be directly placed into a patient's blood
circulation, such as alongside a central line (vein or artery).
Therefore, the term "circulating blood" used herein includes
naturally circulating blood in vivo, and a blood circulation
generated in vitro, such as a blood sample contained in the
blood circulation system 200 of FIG. 1.
Examples 1 and 2 illustrate specific examples of a singlemode optical coagulation monitor and a multi-mode optical
coagulation monitor, respectively.
The principle and mechanism utilizing low-coherence
dynamic light scattering and a single-mode optical fiber for
analyzing mechanical properties of a small volume of liquid
has been fully described in U.S. Pat. No. 6,958,816, which is
hereby incorporated by reference in its entirety. Furthermore,
the principle and mechanism utilizing low-coherence
dynamic light scattering and a multi-mode, common-path
interferometry for analyzing mechanical properties of a small
volume of liquid has been fully described in patent application Ser. No. 11/399,632, which is hereby incorporated by
reference in its entirety.
A whole blood sample is measured using the devices
described in Examples 1 and 2, respectively. FIG. 3 shows the
obtained power spectra. As shown, the power spectrum (intensity vs. frequency) obtained using the multi-mode optical
fiber (curve B) has substantially higher intensity than the
power spectrum obtained using the single-mode optical fiber
(curve A). Additionally, different from the single-mode optical fiber, the power spectrum obtained using the multi-mode
optical fiber does not flatten, which indicates that the multimode signal is not impacted by the noise floor, as is with the
single-mode signal. Therefore, substantial improvements of
signal amplitude and signal-to-noise ratio have been achieved
in measuring whole blood samples using the multi-mode
optical fiber in comparison to the single-mode optical fiber.

The method of using the instant optical coagulation monitors described above for coagulation measurement in vitro or
monitoring blood coagulation status in vivo or in vitro are
described hereinafter.
It should be understood that the instant method is based on
measurement of the mechanical fluctuations of blood cells in
whole blood. When irradiated, the blood cells scatter light in
a random manner as determined by their mechanical movements. When the blood clotting progresses, the blood cell
movement is affected and their limited displacement is
detected via modifications in the fluctuations of the scattered
light. The information regarding the clotting process, either
being induced in vitro or naturally occurring in vivo such as
thrombosis, is then inferred from the temporal autocorrelation of the light fluctuations or from the power spectrum, as
described more fully hereinafter.
Since in blood the number of red blood cells is approximately two orders higher than the number of white blood
cells, the dynamic light scatter signals of the blood cells are
predominantly from the red blood cells. Other components in
the blood, such as proteins in the plasma can also contribute to
the dynamic light signals, however, to a substantially lower
extent. Therefore, the signals from the red blood cells are the
dominant components of the dynamic light scatter signals. It
is noted that the detected light signals further include the
reflected light signals at the interface between the sampling
end of the optical fiber and the blood.
For the purpose of monitoring blood coagulation status or
measurement of blood clotting time, it has been found that a
low-coherence light having a frequency range from 600 run to
700 run can be used. Preferably, the coherence length is from
about 5 µm to about 20 µm, more preferably, from about 8 µm
to about 15 µm. The coherence volume is a volume of the
blood immediately adjacent to the sampling end of the optical
fiber, defined by the coherence length multiplied by the area
of the fiber core. For example, when a multi-mode optical
fiber having a fiber core diameter of 45 µm is used, with a
coherence length of about 10 µm, about 15 fl of the blood
sample is measured. Preferably, a multi-mode optical fiber is
used to achieve higher detection sensitivity and higher signalto-noise ratio.
In one embodiment, the blood clotting time is measured in
vitro using the instant optical coagulation monitor. The
method entails the following steps: mixing a coagulation
initiator with a blood sample to form a sample mixture; transmitting a low-coherence light into the sample mixture; detecting dynamic light scatter signals generated by blood cells of
the sample mixture within a coherence volume; analyzing the
dynamic light signals in comparison to a predetermined clotting criterion; and reporting the blood clotting time of the
blood sample.
Various coagulation initiators known in the art can be used
for the purpose of the present invention. Suitable examples
include, but are not limited to, elite, kaoline, glass cocktail,
silica or phospholipids. Furthermore, the blood clotting time
can also be measured without introducing coagulation initiator, i.e., natural clotting of the blood in vitro.
As described above, when the blood clotting progresses,
the blood cell movement is affected and their limited displacement is detected via modifications in the fluctuations of
the scattered light. The dynamic light scatter signals are predominantly from the red blood cells.
It is known, the shear stress a in a flowing fluid represents
the force exerted by the fluid per unit surface area of a plane
parallel to the direction of flow and is given by
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wherein ri is the shear viscosity and y is the shear rate. The
shear stress a(t) introduced by a small-amplitude deformation is sinusoidal and is defined as
a(t)~y 0 [G'( w )sin( wt)+G"( w )cos(wt)]

x'(w)=~P[x"(<f)a.;
2d<f,
7r
'::i -w

(2)

a regime known as the linear viscosity regime, where w is the
angular frequency. The coefficient of the first term, G'( w), in
phase with the strain, is know as the storage modulus, and
G"(w), corresponding to the term in phase with the rate of
strain, is known as the loss modulus. The former represents
the storage of elastic energy by the fluid, the latter represents
viscous dissipation. The ratio, known as the loss tangent, is
defined as

10

15
G"/G'o=tanli

(3)

and is a measure of the fluidity of the material; i.e., tan 11>> 1
for liquid-like materials, while the opposite holds for solidlike materials. The storage and loss moduli collectively are a
complex function G*, known as complex shear modulus,
G*=G'+iG"

20

(4)

Wherein i=(-1 ) 112 . The complex viscosity is then defined as

The frequency-dependence of the storage and shear moduli
provides information to the structure of complex materials.
For liquid-like materials, one has
G'<<G"

25

30

(5)

and G' is proportional to w2 ; G" is proportional to w, whereas
for solid-like materials both are independent of frequency, but
G'>>G".
In one embodiment of the present invention, the measurable quantity is a power spectrum of the scattered light fluctuations P(w). It has been found that in the high-frequency
region, P( w) is directly related to the power spectral density of
the particle displacements (llr2 ( w) ):

35

40

(6)

45

The high-frequency dependence of the shear modulus G(w)
can be expressed by:
50

1

1

G(w)=--,
fora x(w)

(7)

55

wherein a is the radius of the light scattering particles, and
xC w) comprises two parts, the storage response x'C w) and loss
response x"(w) that characterizes the fluid through
60
w
x"(w) = 2ksT -(Ll.r2(w)),

(9)

(8)

65

and the storage x'(w) and loss response x"(w) are related
through the Kramers-Kronig relationship:

Thus, both G' and G" can be extracted from the measured
power spectrum of the blood sample.
As illustrated in FIG. 3, the obtained power spectrum is a
two dimensional curve of intensity vs. frequency. Based on
one or more of the spectral features, such as shape, slope,
shear modulus G( w) including the storage modulus G'( w) and
the loss modulus G"(w), and other derived parameters, the
predetermined clotting criterion can be determined using a
known blood clotting time of a reference. In one example, the
rate of change in the slope of a power spectrum is used as the
predetermined clotting criterion. In another example, the
storage modulus G'( w), the loss modulus G"( w), or the combination thereof is used as the predetermined clotting critenon.
It should be understood that all parameters described
above, the power spectrum, G', G", and tano, have a dependence on frequency w. Therefore, the predetermined clotting
criterion can be established in terms of the absolute value of
one or more parameters in a narrow frequency range or via a
global estimation over the entire spectral range available to
the measurement.
It is further noted that the power spectrum is a result of
measurement of the dynamic light scatter signals in frequency domain. Alternatively, the dynamic light scatter signals can also be measured in time domain. In other words,
instead of analyzing the power spectrum one, can perform the
entire analysis in the "time domain". More specifically, in the
time domain measurement the dynamic light scatter signals
from the detector are not fed into a power spectrum analyzer,
instead, one evaluates the autocorrelation of the time series
representing the detector output. This temporal autocorrelation has a simple Fourier transform relationship with the
power spectrum. It should be understood that the information
revealed from either the power spectrum or temporal autocorrelation is the same.
As such, in a further embodiment, the dynamic light scatter
signals of a blood sample are recorded and the temporal
autocorrelation is determined. The predetermined clotting
criterion can be a predetermined value or a range of one or
more parameters obtained from the temporal autocorrelation,
such as one or more parameters defining the shape of the
autocorrelation function from a reference, or a predetermined
amount of change in the shape or width of the time autocorrelation.
It should be understood that for measuring blood clotting
time in vitro, not only the sample probe 20 or 120 comprising
an optical fiber as described above can be used for the measurement, an open system as those illustrated in FIGS. 10 and
11 ofU.S. Pat. No. 6,958,816 can also be used. Furthermore,
in this embodiment the sample mixture can be either in a
circulating or a static condition. In the latter case, the sample
mixture can also be simply placed in a sample well, allowing
placement of the sampling end of the optical fiber within the
well or configured to receive the incident light from the open
system.
The red blood cell concentration in the normal peripheral
blood is from about 4.2 to 5.9xl 0 12 cells per liter. Hematocrit
(Hct) is defined as the proportion of blood volume that is
occupied by red blood cells. The normal hematocrit range for
male is from about 45% to about 52%, and for female is from
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about 37% to about 48%. As described above, the dynamic
light scatter signals are predominantly from the red blood
cells, the dependency of the dynamic light scatter signals on
the red blood cell concentration of a sample has been
assessed.
As shown in Example 3, the sensitivity of the power spectrum to the hematocrit (Hct) level was measured using the
multi-mode optical coagulation monitor described in
Example 2. Reconstructed anti-coagulated whole blood
samples with different hematocrit were used for the measurement. More specifically, a series of whole blood samples with
increasing amounts of red blood cells from plasma only, Hct
of 30%, 35%, 40%, 45%, and 50% are measured. Among
these reconstructed whole blood samples, the samples having
Hct of 40%, 45%, and 50% are within the clinical normal
range.
FIG. 4 displays the obtained power spectra, which shows
the dependency of the power spectrum on the hematocrit of
the whole blood samples in the hematocrit range tested. However, within the clinical normal hematocrit range, the power
spectra are essentially independent of the hematocrit of the
blood samples.
Table 1 shows the parameter a obtained by linear fitting of
the power spectrum measured at high frequencies, which is
indicative of the type of diffusion regime. A strong dependence of a on the hematocrit has been observed. This observation indicates a tendency towards normal diffusion (a=l),
when the hematocrit increases. Since the intensity of the
signal obtained for plasma only is much lower than the intensity of the sample having 40% Hct, it can be concluded that
for the whole blood samples having hematocrit within the
clinical normal range, the heterodyne signal is mainly due to
the motion of the red blood cells.
Example 4 illustrates the measurement of dynamic viscosity change during thrombosis of a whole blood sample using
the multi-mode optical coagulation monitor described in
Example 2. As shown, after introducing thrombin into the
whole blood sample, coagulation occurred as indicated by the
change of the power spectrum with time due to increase in
viscosity. After 22 minutes, a clot formed in front of the
optical fiber, and no further change was noted in the spectrum
afterwards. FIG. 5 shows the obtained power spectra of the
blood sample at 7, 15 and 22 minutes. Moreover, FIG. 5
further shows the power spectrum of washed red blood cells
suspended in PBS, which represents the minimum viscosity
obtainable using erythrocytes suspended in a medium with a
viscosity close to water.
The results show that the instant optical coagulation monitor can detect both reduction and increase in viscosity of the
blood samples. In the case of increased viscosity due to blood
coagulation, sequential increases are observed to the point of
gel formation due to clotting.
This result demonstrates that the process of blood clotting
can be dynamically tracked over a period of time by measurement of increasing viscosity. This is particularly relevant in
the context of early detection of onset of thrombosis in clinical settings such as in intensive care units. Patients who have
undergone major surgery are at great risk of thrombosis up to
72 hours after surgery. Under these conditions any significant
increase in blood viscosity may most probably indicate the
onset of thrombosis. Using the instant optical coagulation
monitor in vivo such as in the patient's circulation (possibly
alongside a central line or canula ), as described in the further
embodiment of the present invention hereinafter, could provide early detection of clotting activation, therefore, therapeutic intervention could be started to avert overt thrombosis
and death.

Example 5 further illustrates a specific method using the
change in the shape of the power spectra with time for measurement of blood clotting time of whole blood samples. As
shown, after introducing thrombin into a whole blood sample,
blood coagulation occurred within about 5 to 7 minutes, and
an increase in viscosity was observed over time as illustrated
in FIG. 6. Sequential increases of the blood viscosity were
observed to the point of gel formation due to clotting.
FIG. 6 shows an expanded region of the collected power
spectra, and a significant decrease in the bandwidth is
observed. It has been found that the actual changes in the
viscosity properties are best demonstrated by the changes in
the shape of the power spectra. FIG. 7 is a log-log representation of the power spectra shown in FIG. 6. As can be readily
appreciated from FIG. 7, the slope of the power spectrum
changes significantly as the aggregation process evolves.
Quantitative determination of the viscoelastic properties can
be made based on these changes of the spectra. It is noted that
when the change in the slope of the spectrum is used as the
parameter for determining the blood clotting time, the measurement is independent of the absolute value of the initial
viscosity of a blood sample. This result illustrates that the
optical coagulation monitor and the method of the present
invention can be used for a quantitative measurement ofblood
clotting time.
It is known that the two major proteins in blood are albumin
(normal range 60-80 mg/ml) and fibrinogen (normally about
3 mg/ml). Albumin is primarily responsible for the viscosity
of blood, and it is important in regulating osmotic pressure
and water retention in the circulation. Fibrinogen concentration gradually increases with age to concentrations of 6
mg/ml or more in both males and females, therefore, it is a
risk factor for cardiovascular disease.
The sensitivity of the instant optical coagulation monitor to
the difference in fibrinogen and albumin concentrations, and
the viscosity change affected by the proteins has also been
assessed. Example 6 illustrates two specific examples.
In the first example, washed red blood cells were suspended in PBS with a hematocrit of 45%, and in PBS solutions that contained 1.3 and 5.5 mg/ml offibrinogen, respectively. As described above, the washed red blood cells
suspended in PBS alone represent the minimum viscosity
detectable using erythrocytes as the viscosity reporters, since
the viscosity of PBS is close to that of water, and significantly
less than that of plasma. The power spectra of these three
suspensions were obtained using the multi-mode optical
coagulation monitor described in Example 2. As shown, the
viscosity increased with the concentration of fibrinogen.
Moreover, the increase in viscosity observed at a fibrinogen
concentration of 1.3 mg/ml indicated that the multi-mode
optical coagulation monitor of the present invention was sufficiently sensitive to detect small changes in fibrinogen concentration.
In the second example, the washed red blood cells were
suspended in PBS with a hematocrit of 45%. Albumin was
added into the circulation of the red blood cell suspension and
the power spectra were recorded after the addition of the
protein. FIG. 9 shows the obtained power spectra of blood
cells in PBS, and with addition of 500 µl and 1000 µl of
albumin, respectively. As shown, addition of albumin to
washed erythrocytes increased viscosity in a similar manner
to fibrinogen, further indicating the ability of the instant
monitor in detecting changes in viscosity induced by proteins.
Since these proteins are the major components of plasma, the
results of Example 6 have further indicated the utility of the
instant optical coagulation monitor in monitoring of coagulation status in vivo, as described more fully hereinafter.
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In a further embodiment, the present invention provides a
method of determining or monitoring the coagulation status
in vivo or in vitro in real time. The method entails the following steps: positioning a sample probe comprising an optical
fiber within a circulating blood, transmitting a low-coherence
light through the optical fiber into the blood, detecting
dynamic, light scatter signals generated by the blood within a
coherence volume and received through the optical fiber,
analyzing the dynamic light signals in comparison to a predetermined coagulation criterion, and reporting a coagulation
status of the blood.
Herein, the term "coagulation status" refers to a blood
property relating to coagulation process, such as viscosity of
a whole blood, or a change of a blood property relative to
time, such as blood viscosity change before, during and after
a surgical procedure, or relative to a treatment, such as procoagulant or anticoagulant therapy.
For determination of the coagulation status, the predetermined coagulation criterion can be any one of those parameters described above that can be used as a predetermined
clotting criterion, either in the frequency domain or the time
domain. For example, using the shape, slope, shear modulus
G( co) including the storage modulus G'( co) and the loss modulus G"( co), or other derived parameters of a power spectrum,
or the shape or change of the shape or width of the temporal
autocorrelation, the predetermined coagulation criterion can
be determined with a known value of the parameter from a
reference. In one example, the predetermined coagulation
criterion is the average value of the loss tangent obtained from
the measurement of one or more normal subjects. In another
example, the predetermined coagulation criterion is a predetermined amount of change in the width or the shape of the
temporal autocorrelation obtained from the measurement of
one or more normal subjects.
Moreover, in terms of monitoring, the predetermined
coagulation criterion can be one or more of the above
described parameters at a reference point of the patient's own
blood, for example, the average value of the loss tangent
obtained from a patient prior to beginning a surgical procedure, or a clinical treatment. The predetermined coagulation
criterion can also be an external reference, for example, a
threshold for detection of thrombosis established based on
clinical statistics or reference controls.
Furthermore, it should be understood that the predetermined coagulation criterion can also be established based on
(i) "instantaneous" measurement of one or more of these
parameters, or (ii) the time evolution of one or more of these
parameters. "Instantaneous" measurement means one rapid
measurement of the power spectrum (typically few seconds),
while the time evolution of a parameter is followed for a
longer period of time (for example minutes, or tens of minutes). The predetermined coagulation criterion can be determined with a known instantaneous value of the parameter
from a reference or can be determined with a known time
dependence of the parameter from a reference.
To function as an in vivo diagnostic indicator, one or more
of the selected parameters can be illustrated in a manner
convenient for the clinical practitioners to use. The predetermined coagulation criterion can be expressed as a threshold or
a defined acceptable range. If the selected parameter is below
the threshold or within the range, it indicates a normal coagulation status. Alternatively, when the selected parameter is
above the threshold or outside the range, the report indicates
an abnormal coagulation status. Moreover, since the magnitude of the parameter is quantitative, severity of the patient's
condition can also be detected in real time.

As can be appreciated, since the instant method detects the
coagulation status in vivo in real time, the patient's response
to a drug, either increasing or reducing the risk of clotting, can
be monitored and timely reported. As such, important information, such as the rate of response, adverse response if any,
and stability of coagulation condition, can be revealed using
the instant method. This real time detection capacity has
never been achieved previously with existing technologies.
The instant method can also be used to evaluate risk of
excessive bleeding prior to a surgical procedure (i.e., presurgical screening), monitor bleeding disorders, and can be
used for point-of-care testing to monitor a patient's blood
coagulation level within therapeutic range, real-time assessment of coagulophaties, or used postoperative to monitor
medication effects.
As a specific example, the instant method can be used to
monitor the effectiveness of procoagulant or anticoagulant
therapies, and particularly to monitor the effect of therapeutic
intervention of thrombosis, for example, monitoring a patient
under the treatment of a fibrinolytic agent, such as streptokinase. Using the instant optical coagulation monitor, the physician can observe the arrest of viscosity increase due to
inhibition of clotting, as well as subsequent viscosity
decrease as fibrin oligomers and polymer strands are broken
down to smaller, less viscous fibrin degradation products.
The instant multi-mode optical coagulation monitor as
illustrated in FIG. 2 and described in Example 2 is currently
used for research purpose in a clinic for monitoring patients'
coagulation status during surgical procedures (such as a cardiopulmonary bypass). This, for the first time, enables in vivo
monitoring of a patient's coagulation status in real time in a
clinical environment. Therefore, the present invention provides a significant breakthrough in the early detection of the
onset of thrombosis. The resultant early therapeutic intervention can undoubtedly save lives.
The following examples are illustrative of the invention
and are in no way to be interpreted as limiting the scope of the
invention, as defined in the claims.
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An optical coagulation monitor as shown schematically in
FIG. 1 was constructed. The major components are described
below.
Light source (50) was a superluminiscent diode (SLD)
from SUPERLUM (Russia), which had the spectral bandwidth ofFWHM 9.0 nm, centered at 676.2 nm. The spectral
ripple of the light source was about 0.4% and photodiode
current was around 0.954 mA. The SLD was pigtailed with
single-mode optic fiber having a fiber inner jacket of 125 µm
thick, a fiber core thickness of 8 µm, and FC/APC termination. SLD current and temperature controller (40) was a
PILOT-2 from SUPERLUM. Optical isolator (60) was a
single-mode optical fiber with a wavelength of 630 nm from
Optics for Research (Caldwell, N.J.). The fiber inner jacket
was 125 µm thick, and the fiber core thickness was 8 µm.
Terminators were FC/PC.
The sample probe (20) comprised a needle (22) with a
single-mode optical fiber (80) disposed within. The needle
was a 23 gauge (one inch length) Precisionglide from BD
(Franklin Lakes, N.J.). A single-mode optical fiber from
Thorlabs (Newton, N.J.) was used, which had a wavelength of
630 nm, a fiber inner jacket of 125 µm thick, and a fiber core
thickness of 8 µm. The terminators were FC/PC.
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Fiber optic splitter (100) was a 2xl splitter type from
Newport (Irvine, Calif.). The fiber type was single-mode fiber
with a wavelength of 630 nm. Terminators were FC/PC. The
fiber inner jacket thickness was 125 µm, and the fiber core
thickness was 8 µm.
The optical detector (70) was a Model 2001 from New
Focus (San Jose, Calif.) which was carefully chosen to provide low-noise detection, variable-gain transimpedance
amplification of up to 90 dB in 10-dB steps, and two adjustable frequency filters. This particular design allowed selecting the frequency region of interest before additional amplification. The high-pass filter could be adjusted to eliminate
residual 60-Hz noise, while the independent low-pass filter
could be set to select the bandwidth of interest therefore
allowing for efficient and rapid measurements.
A two-channel dynamic light signal analyzer (110), SR785
from Stanford Research Systems (Sunnyvale, Calif.) was
used to receive and process the light signals. The analyzer was
usually operated in the FFT mode with a base Frequency of
100 Hz and 800 FFT lines. The data viewer, SR785 Data
Viewer (Version 1.0) from Stanford Research Systems, was
accessed via GPIB to provide further data processing by a
personal computer (120).
The blood circulation system (200) included a sample
chamber (210), of which inlet 212 and outlet 214 were connected to two opposing ends of a silicone tubing 8060-0020
from Nalgene (Rochester, N.Y.). A Peri-Star 500291 high
performance digital peristaltic pump (230) from World Precision Instruments (Sarasota, Fla.) was used. The pump had a
fluid flow range of 0.1-80 ml/min. A microprocessor controlled 280 Series water bath from PRECISION (Champaign,
Ill.) was used. The temperature was controlled at about 3 7° C.
during the measurement of blood samples.

each sample, and the optical fiber of the sample probe was
cleaned after measurement of each sample. The whole blood
collected in acid citrate dextrose (ACD) was supplied by
Valley Biomedical Products and Services, Inc. (Winchester,
Va.).
The temperature of the blood sample in the sample chamber in the measurements of the samples having Hct of 30%
and 35% was at 36.6° C., in the measurements of plasma, and
samples having Hct of 40% and 45% was at 35.6° C., and in
the measurements of the sample having Hct of 50% was at 37°
C., respectively. Each sample was circulated for 5 minutes on
the pump at a flow rate of 0.87 ml/min, before the power
spectrum was recorded. The light source was operated at 90
mA.
FIG. 4 shows the obtained the power spectra, wherein each
curve represents an average of 200 measurements of the
power spectrum. As shown, the power spectra of the whole
blood samples depended on the hematocrit of the whole blood
samples within the hematocrit range tested. However, within
the clinical normal hematocrit range, the power spectra were
essentially independent of the hematocrit of the blood
samples.
Table 1 shows the parameter a obtained by linear fitting of
the power spectrum measured at high frequencies, which was
indicative of the type of diffusion regime. A strong dependence of a on the hematocrit was observed. This observation
indicated a tendency towards normal diffusion (a=l), when
the hematocrit increased. Since the intensity of the signal
obtained for plasma only was much lower than the intensity of
the sample having a Hct of 40%, it could be concluded that for
the whole blood samples having hematocrit within the clinical normal range, the heterodyne signal was mainly due to the
motion of the red blood cells.

EXAMPLE2
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A Multi-Mode Optical Coagulation Monitor
A multi-mode optical coagulation monitor (300), as shown
schematically in FIG. 2, was constructed.
A single-mode optical fiber (60a ), as described in Example
1, was connected to the light source at one end, and was
coupled to a multi-mode optical fiber (360) at the opposing
end by a coupler (330). The multi-mode optical fiber (60b)
was in tum connected to the coupler (llOb ). Both multi-mode
optical fiber (60b) and sample branch (380) were a graded
index multimode fiber from Newport (Irvine, Calif.), which
operated at a wavelength of 630 nm and had a core thickness
of 56 µm. The terminators were FC/PC.
All other components, including light source, SLD current
and temperature controller, detector, two-channel dynamic
light signal analyzer, personal computer, needle of the sample
probe were the same as those described in Example 1. For in
vitro measurement, the blood circulation system (200)
described in Example 1 can be used.

40

Hematocrit Level

a

0%
(plasma)
30%
35%
40%
45%
50%

0.14
0.2
0.45
0.75
0.82
0.76
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EXAMPLE3
Dependence of Power Spectrum on the Hematocrit
60

The sensitivity of the power spectrum to the hematocrit
(Hct) was measured using the multi-mode optical coagulation
monitor described in Example 2.
A series of 4 ml reconstituted blood samples with increasing amounts of red blood cells: plasma, Hct of 30%, 35%,
40%, 45%, and 50% were used for the measurement. The
tubing and needles were changed for the measurement of

TABLE 1
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Measurement of Dynamic Viscosity Change during
Thrombosis
3.8 ml of an anti-coagulated whole blood sample was
placed into the sample chamber of the multi-mode optical
coagulation monitor described in Example 2. The whole
blood sample had a hematocrit of 45%. The temperature of
the blood was controlled at 35.8° C. during the measurement,
and the flow rate of the pump was at 0.87 ml/min. The light
source was at 90 mA.
12 µl ofthrombin (100 U/ml) was added into the circulating
blood in 3 µl increments every 10 minutes over a period of 20
minutes. The thrombin was pre-diluted in a phosphate buffer
saline (PBS). The power spectra were recorded after each
injection every 30 seconds for 10 minutes, no change of the
power spectrum was observed. Then, additional 6 µl ofthrombin was added into the blood, and the power spectra were
recorded every 30 seconds for 30 minutes. As shown in FIG.
5, changes in viscosity with time were observed. After 22
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minutes, a clot formed in front of the optical fiber, and no
further change was noted afterwards. FIG. 5 showed the
obtained power spectra at 7, 15 and 22 minutes. Each curve
was averaged 200 times. FIG. 5 further showed washed red
blood cells suspended in PBS, which represented the minimum viscosity obtainable using erythrocytes suspended in a
medium with a viscosity close to water. The results showed
linear responses across the spectral range.

silicone tubing placed after the pump and preceding the
sample chamber. The power spectra were recorded after the
addition of the protein. FIG. 9 showed the obtained power
spectra of blood cells in PBS, and with addition of 500 µl and
1000 µl of albumin, respectively. As shown, addition of albumin to washed erythrocytes increased viscosity in a similar
manner to fibrinogen, again indicating the ability of the monitor in detecting changes in viscosity induced by proteins.
While the present invention has been described in detail
and pictorially shown in the accompanying drawings, these
should not be construed as limitations on the scope of the
present invention, but rather as an exemplification of preferred embodiments thereof. It will be apparent, however, that
various modifications and changes can be made within the
spirit and the scope of this invention as described in the above
specification and defined in the appended claims and their
legal equivalents.

EXAMPLES

10

Measurement of Blood Clotting Time of Whole
Blood Samples
The blood clotting time was measured using the multimode optical coagulation monitor described in Example 2
with the blood circulation system described in Example 1.
The instrument setting described in Example 4 was used. The
two units of whole blood were collected inACD (from Valley
Biomedical Products and Services, Inc.), and had a hematocrit of 45% and 41 %, respectively.
3 µl of thrombin per 3 ml of blood were mixed with the
blood and directly aspirated at a pump speed of 5-1.2 ml/min
into the blood circulation system. The power spectrum was
recorded immediately, and every 30 seconds thereafter. Blood
coagulation occurred within about 5 to 7 minutes, and an
increase in viscosity was observed over time as illustrated in
FIG. 6. Sequential increases of the blood viscosity were
observed to the point of gel formation due to clotting.
FIG. 6 showed an expanded region of the collected power
spectra and a significant decrease in the bandwidth was
observed. The actual changes in the viscosity properties were
best demonstrated by the changes in the shape of the power
spectra. FIG. 7 was a log-log representation of the power
spectra. As shown, the slope of the power spectrum changed
significantly as the aggregation process evolved.
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EXAMPLE6
Detection of the Effect of Protein Concentration on
Blood Viscosity
In the first test, a whole blood collected in ACD (from
Valley Biomedical Products and Services, Inc.) was centrifuged, and the plasma fraction was removed and washed
(twice to remove all plasma) with PBS. The washed red blood
cells were suspended in PBS alone and in PBS solutions that
contained 1.3 and 5 .5 mg/ml of fibrinogen, respectively. The
reconstituted blood cell suspension had a hematocrit of 45%.
The power spectra of these three suspensions were
obtained using the multi-mode optical coagulation monitor
described in Example 2 with the blood circulation system
described in Example 1. The temperature was controlled at
36° C. and the flow rate was 0.87 ml/min. The light source was
at 90 mA. The obtained power spectra were shown in FIG. 8.
As shown, the viscosity increased with the increase of the
concentration of fibrinogen. Furthermore, the increase in viscosity observed at a fibrinogen concentration of 1.3 mg/ml
indicated that the instant monitor was sufficiently sensitive to
detect small changes in fibrinogen concentration.
In the second test, the washed red blood cells were suspended in PBS with a hematocrit of 45%. The power spectra
of the blood cell suspension were obtained using the same
device under the same condition, except the temperature was
at 36.5° C.
An albumin solution was made at a concentration of 50
mg/ml and was added slowly through an injection port of the
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What is claimed is:
1. An optical coagulation monitor comprising:
(a) a sample chamber including an inlet and an outlet
connected to a circulation path;
(b) a light source providing a low-coherence light;
(c) a sample probe disposed within said sample chamber,
said sample probe comprising an optical fiber optically
connected to said light source for transmitting said lowcoherence light into a blood sample contained in said
sample chamber;
(d) an optical detector connected to said sample probe for
detecting light signals received from said sample probe;
(e) a dynamic light signal analyzer connected to said optical detector for analyzing said dynamic light scatter
signals in comparison to a predetermined coagulation
criterion; and
(f) a viewer for reporting a coagulation status of said blood.
2. The optical coagulation monitor of claim 1 further comprising a pump connected to said circulation path to circulate
said blood sample through said sample chamber.
3. The optical coagulation monitor of claim 1, wherein said
optical fiber comprises a single-mode optical fiber or a multimode optical fiber.
4. The optical coagulation monitor of claim 1 further comprising an optical coupler connecting to said optical fiber, said
light source, and said optical detector for directing said lowcoherence light from said light source into said optical fiber
and directing said light signals received from said sample
probe to said optical detector.
5. The optical coagulation monitor of claim 1, wherein said
light source comprises a superluminescent diode, a multiple
quantum well light emitting diode, a modelocked Ti:Al 2 0 3
laser, a laser pumped fluorescent organic dye, or a superfluorescent optical fiber.
6. The optical coagulation monitor of claim 1, wherein said
low-coherence light has a coherence length of about 5 µm to
about 20 µm.
7. A method of determining or monitoring blood coagulation status comprising:
(a) positioning a sample probe comprising an optical fiber
within a circulating blood;
(b) transmitting a low-coherence light through said optical
fiber into said blood;
(c) detecting dynamic light scatter signals generated by
said blood within a coherence volume and received
through said optical fiber;
(d) analyzing said dynamic light scatter signals in comparison to a predetermined coagulation criterion; and
(e) reporting a coagulation status of said blood.
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8. The method of claim 7, wherein said low-coherence light

has a coherence length of about 5 µm to about 20 µm.
9. The method of claim 7, wherein said optical fiber comprises a single-mode optical fiber or a multi-mode optical
fiber.
10. The method of claim 7, wherein said detecting said
dynamic light scatter signals generates a power spectrum of
intensity vs. frequency.
11. The method of claim 10, wherein said predetermined
coagulation criterion is a predetermined value or a range of
one or more parameters obtained from said power spectrum.
12. The method of claim 11, wherein said predetermined
coagulation criterion is a shape or a rate of change in said
shape of said power spectrum.
13. The method of claim 11, wherein said predetermined
coagulation criterion is a predetermined amount of change of
storage modulus G'.
14. The method of claim 11, wherein said predetermined
coagulation criterion is a predetermined amount of change of
loss modulus G".
15. The method of claim 11, wherein said predetermined
coagulation criterion is a predetermined amount of change of
loss tangent tano.
16. The method of claim 7, wherein said detecting said
dynamic light scatter signals of said blood cells generates
temporal autocorrelation of said dynamic light scatter signals.
17. The method of claim 16, wherein said predetermined
coagulation criterion is a predetermined value or a range of
one or more parameters obtained from said temporal autocorrelation.

18. The method of claim 17, wherein said predetermined
coagulation criterion is a predetermined amount of change in
the shape of said temporal autocorrelation.
19. The method of claim 17, wherein said predetermined
coagulation criterion is a predetermined amount of change in
the width of said temporal autocorrelation.
20. The method of claim 7, wherein said circulating blood
IS Ill VIVO.
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21. The method of claim 7, wherein said circulating blood
is in vitro.
22. The method of claim 7, wherein said monitoring blood
coagulation status is in real time.
23. A method of determining blood clotting time comprising:
(a) mixing a coagulation initiator with a blood sample to
form a sample mixture;
(b) transmitting a low-coherence light into said sample
mixture;
(c) detecting dynamic light scatter signals generated by
said sample mixture within a coherence volume;
(d) analyzing said dynamic light scatter signals in comparison to a predetermined clotting criterion; and
(e) reporting said blood clotting time of said blood sample.
24. The method of claim 23, wherein said sample mixture
is in a flowing or static condition during said detecting
dynamic light scatter signals.
25. The method of claim 23, wherein said low-coherence
light has a coherence length of about 5 µm to about 20 µm.
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